Bromantane
Research Guide

Research Overview

Bromantane is an adamantane-derived small molecule (CAS 87913-26-6) studied in the preclinical literature as an actoprotector, a class of compounds reported to raise resistance to physical load without increasing oxygen consumption or heat production. It has also been characterized as a synthetic adaptogen and an atypical psychostimulant with anxiolytic properties in animal and non-controlled clinical reports. Note this is a small molecule, not a peptide.

The compound was developed at the Zakusov State Institute of Pharmacology in the USSR during the 1980s and was later marketed in Russia under the brand name Ladasten. It has no FDA or EMA approval, and its regulatory and scheduling status outside Russia was not verified in this research run. Investigators should confirm the legal status of any material in their own jurisdiction.

This page consolidates identity data retrieved live from PubChem with mechanism and research-context findings drawn from the primary and review literature cited below. It is written for laboratory reference only. Every lot-specific value, including physical form and HPLC purity, should be confirmed against the batch Certificate of Analysis (COA).

Mechanism Summary

Mechanisms reported in the in-vitro and preclinical research literature include:

• Bromantane is most directly documented as a dopaminergic modulator that acts at the level of gene expression rather than as a direct reuptake inhibitor, a feature that distinguishes it from classical stimulants in the retrieved literature.
• In rats given a single 50 mg/kg oral dose, Mikhaylova et al. 2007 (Neuropharmacology, PMID 17854844) reported that bromantane differentially regulated tyrosine hydroxylase (TH) mRNA and protein alongside dopamine and L-DOPA content across the ventral tegmental area, nucleus accumbens, hypothalamus, striatum, and hippocampus. The same work reported that bromantane converted short-term hippocampal potentiation into a longer-lasting form via a protein-synthesis-dependent, dopamine D1/D5-dependent mechanism, an effect blocked by anisomycin and attenuated by SCH23390.
• Consistent with a transcriptional or epigenetic route, Salimgareeva et al. 2011 (PMID 22235395) reported that a single 50 mg/kg dose altered histone deacetylase 1 (HDAC1) and acetylated histone H3(Lys9) and H4(Lys8) levels in rat striatum, hippocampus, and hypothalamus. A neurotoxicology screen by Iezhitsa et al. 2002 (PMID 12124651) linked its behavioral effects to central dopaminergic stimulation with suppression of muscarinic and nicotinic cholinergic signaling.
• Review-level sources additionally describe reported GABAergic and serotonergic contributions and antiradical or membrane-protective properties (Oliynyk & Oh 2012, PMID 24009833). The precise upstream molecular trigger for the reported TH regulation is not established in the primary literature retrieved this run. All findings above are in-vitro, animal, or non-controlled clinical reports; no human efficacy is asserted.

Reference Data

Identity values are compiled from public chemistry databases and vendor documentation. Confirm the exact salt form, molecular weight, and purity for a given batch against its Certificate of Analysis (COA).

Research Applications

In laboratory research, Bromantane is studied in contexts such as:

• Studied preclinically as an actoprotector or adaptogen in models of resistance to physical load, fatigue, hypoxia, and hyperthermia (reviewed in Oliynyk & Oh 2012, PMID 24009833).
• Investigated in animal models and early Russian clinical reports for asthenia and asthenic or psychogenic disorders under the name Ladasten (pilot trial, Siuniakov et al. 2006, PMID 16995430; RCT-context self-assessment analysis, Neznamov et al. 2012, PMID 22834121).
• Investigated as a dopaminergic modulator of catecholamine biosynthesis and hippocampal synaptic plasticity in rats (Mikhaylova et al. 2007, PMID 17854844).
• Studied for reported anti-inflammatory and immunomodulatory effects, including reduced LPS-induced TNF-alpha and IL-6 in a mouse depression-like model (Tallerova et al. 2011, PMID 22803040) and normalized T-lymphocyte subpopulations in a chronic-stress mouse model (Tallerova et al. 2014, PMID 24771370).
• Investigated at the molecular level through brain proteomics and histone-modification profiling to map target proteins and epigenetic effects (Yamidanov et al. 2010, PMID 21165444; Salimgareeva et al. 2011, PMID 22235395).
• Characterized as a doping agent and analytical target in anti-doping science following positive athlete tests at the 1996 Olympics (Burnat et al. 1997, Lancet, PMID 9314900); prohibited by WADA as a stimulant.

Storage Information

• Handling and stability parameters for any specific lot should be confirmed against the batch COA and supplier documentation; solubility and stability specifics were not retrieved in this research run.
• For general laboratory reconstitution and storage of research compounds, see the Disguised Research Lyophilized Storage Guide.
• To plan working concentrations for in-vitro or preclinical study designs, see the Disguised Research Reconstitution Calculator.
• As a small molecule rather than a peptide, storage handling may differ from lyophilized peptide protocols; verify the recommended form and conditions on the COA.

Frequently Asked Questions

What is Bromantane? An adamantane-derived small molecule (CAS 87913-26-6) studied preclinically as an actoprotector and synthetic adaptogen, marketed historically in Russia as Ladasten. Supplied strictly for Research Use Only.

Is Bromantane a peptide? No. It is a small-molecule secondary arylamine on an adamantane scaffold, so peptide-specific purity language does not apply; confirm HPLC purity on the COA.

What mechanism has been reported? Rodent studies report differential regulation of tyrosine hydroxylase and dopamine, plus dopamine-dependent reinforcement of hippocampal plasticity (PMID 17854844) and epigenetic histone effects (PMID 22235395). Preclinical only.

What is its purity and physical form? Both are lot-specific and should be confirmed against the batch COA; no fixed figure is asserted here.

Can it be used in humans? No. Research Use Only, not for human or veterinary use, with no FDA or EMA approval and a WADA prohibition in sport.

Research Use Only

For Research Use Only. Not for human or veterinary use, diagnostic, or therapeutic purposes. All statements describe in-vitro / preclinical research context only.

Catalog

View the Bromantane product listing: /product/bromantane/